tiprankstipranks
Trevi Therapeutics reports Q3 EPS (13c), consensus (12c)
The Fly

Trevi Therapeutics reports Q3 EPS (13c), consensus (12c)

“Our team has made excellent progress advancing our clinical programs this year, and we are eagerly anticipating the upcoming clinical results starting in December,” said Jennifer Good, President and CEO of Trevi Therapeutics (TRVI). “Positive results over the upcoming months would bring us closer to potentially addressing the significant unmet need and market opportunity in both chronic cough in IPF and RCC through Haduvio’s unique mechanism.”

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App